CYTK Cytokinetics, Incorporated
Cytokinetics, Incorporated (CYTK) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $1.54 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -8.7% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Cytokinetics, Incorporated
Cytokinetics Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
Sector
Healthcare
Industry
Biotechnology